Snapshots of risk
What is your early breast cancer patients' risk of developing distant metastases?
In postmenopausal patients with hormone-receptor–positive (HR+) early breast cancer, distant metastases are associated with the lowest survival rates compared with other recurrences.1 And the risk of distant metastases initially peaks just 2 years after surgery.2
But just how great is the risk of distant metastases for patients based on their distinct clinical profiles and breast cancer characteristics? Here, you will read about 4 cases that are representative of those you may see in your practice. Please review the background information on each patient. Then, click on the link following her profile to:
- Answer questions about her case
- Get more information regarding her specific risk of distant metastases and an effective treatment approach
FEMARA® patient case study #1: Michelle
Clinical profile
- Age 68
- Stage IIIA
- Postmenopausal
- Comorbidity: Type 2 diabetes
Breast cancer characteristics
- ER+/PR-
- T2 (4 cm)
- Grade 2
- 4 positive nodes
- HER-2/neu+
- Modified radical mastectomy
- Radiation
FEMARA® patient case study #2: Emma
Clinical profile
- Age 55
- Stage IIB
- Postmenopausal
- Comorbidity: Osteoporosis
Breast cancer characteristics
- ER+/PR+
- T3 (1.5 cm)
- Grade 1
- 2 positive nodes
- HER-2/neu-
- Modified radical mastectomy
- Radiation
FEMARA® patient case study #3: Annette
Clinical profile
- Age 75
- Stage 1
- Postmenopausal
- Comorbidities:
- Type 2 diabetes
- Osteoarthritis
Breast cancer characteristics
- ER+/PR-
- T1 (1 cm)
- Grade 1
- No nodal involvement
- HER-2/neu-
- Lumpectomy
- Radiation
FEMARA® patient case study #4: Astrid
Clinical profile
- Age 55
- Stage I
- Postmenopausal
- Comorbidity: Hypertension
Breast cancer characteristics
- ER+/PR-
- T1 (0.5 cm)
- Grade I
- No nodal involvement
- HER-2/neu-
- Lumpectomy
- Radiation
FEMARA® is indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
Click here for Important Safety Information for FEMARA®.
References 1. Rugo H, Rourke M, Dranitsaris G, Kaura S. Letrozole or anastrozole for the prevention of early recurrences in post menopausal women with early stage breast cancer: using number needed to treat (NNT) to compare benefit (abstract). EJC Supplements. 2008;6(7):118 (Abstract 236). 2. Mansell J, Monypenny IJ, Skene AI, et al. Distant metastasis-the most common type of early recurrence with adjuvant tamoxifen therapy. Poster presented at: 30th Annual San Antonio Breast Cancer Symposium; December 13-16, 2007; San Antonio, Texas.
